Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

A top view of medicine powders, liquids in containers, and various manufactured medicine on the American flag. An America pharmaceuticals concept. | image Credit: ©Ming -stock.adobe.com

The FDA Moves to Modernize Drug Manufacturing Registration

BySusan Haigney

July 10th 2026

Sarclisa Escena is subcutaneous injection designed for 3 multiple myeloma treatment combinations

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

ByZachary Zubulake

July 10th 2026

PharmTech Weekly Roundup–July 10, 2026

BySusan Haigney

July 10th 2026

Teva Pharmaceutical Industries and Polpharma Biologics Collab on Ocrevus (ocrelizumab)

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

ByZachary Zubulake

July 9th 2026

Online documentation database; document management system DMS concept. FTP (File Transfer Protocol), Secure FTP. Internet cloud technology, exchange information and data storage concept. | Image Credit: ©Irene -stock.adobe.com

Structuring Tech Transfer for Optimized Collaboration

ByJamie Evans,Joe Cobb,Susan Haigney

July 9th 2026

Advances in Tableting

Articles in this issue

Related Content

The FDA Moves to Modernize Drug Manufacturing Registration

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

PharmTech Weekly Roundup–July 10, 2026

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

Structuring Tech Transfer for Optimized Collaboration

Trending on Pharmaceutical Technology

The FDA Moves to Modernize Drug Manufacturing Registration

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

Overcoming Raw-Material Variability Challenges for Autologous Adoptive Cell Therapies

PharmTech Weekly Roundup–July 10, 2026

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline